81. Upper Gi Tract Involvement in Children With Crohn's Disease

Lenaerts, C; Weber, Andrée; Maurage, C.; Belli, Dominique Charles; Roy, Claude

doi:10.1203/00006450-198707000-00102

Cited by 33 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Crohn's disease Gastritis and mucosal ulceration is found in 25±40% of children and adults with Crohn's disease, and upper gastrointestinal symptoms are commonly reported in these patients [34]. However, these symptoms often lead children to the evaluation for peptic ulcer disease and the treatment thereof, rather than a work-up for Crohn's disease.…”

Section: Other Disorders Of Acid``hypersecretion''mentioning

confidence: 98%

Gastritis and peptic ulcer disease in childhood

Blecker¹,

Gold

1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Other Disorders Of Acid``hypersecretion''mentioning

confidence: 98%

Gastritis and peptic ulcer disease in childhood

Blecker¹,

Gold

1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…It reveals that 38% of children of all ages have small bowel disease, 38% have small bowel and large bowel disease and 20% have large bowel disease. Other studies have shown that upper GI disease occurs in 30% to 40% of children [29]. Even higher rates (up to 71%) are seen in endoscopic studies [30,31] and perianal disease is found in 11% to 18% [32,33].…”

Section: Paediatric CD Disease Coursementioning

confidence: 95%

The Management of Paediatric Crohn's Disease: Addressing Unmet Needs

Veereman-Wauters¹,

Cucchiara²

2008

TOPEDJ

View full text Add to dashboard Cite

Paediatric Crohn's disease (CD) affects 5 in 100,000 children in the US and Europe and can result in growth retardation and delayed sexual development. Therefore, early diagnosis and treatment is critical, with the goal being maintenance of symptomatic remission and a change in disease course. Conventional treatment relies on aminosalicylate maintenance therapy with corticosteroids to control acute exacerbations and immunomodulators for steroid-resistant or frequently relapsing disease. Infliximab has demonstrated efficacy in moderately to severely active paediatric CD, with 88.4% patients in clinical response and 58.9% in clinical remission at week 10. Significant improvements in quality of life, height, reduction in corticosteroid use and mucosal healing were observed with infliximab. Traditional 'step-up' treatment strategy may be suboptimal because relapse and steroid dependency/resistance rates remain high. A 'top down' approach using biologic therapy earlier may suppress intestinal inflammation and promote prolonged and stable remission, but safety issues need to be considered.

show abstract

“…With the more uniform employment of EGD in pediatric CD patients, the prevalence of UGI involvement in pediatric CD has been better characterized. The pediatric literature suggests that the incidence of macroscopic UGI tract involvement in patients with CD can be as high as 30 % [ 11 ]. The prevalence of microscopic involvement of the UGI tract can be as high as 60 % [ 12 -14 ].…”

Section: Crohn's Diseasementioning

confidence: 99%